- Japan
- /
- Medical Equipment
- /
- TSE:6869
Sysmex (TSE:6869) Is Up 5.5% After Goldman Sachs Upgrade on Improved Growth Outlook—Has the Bull Case Changed?

Reviewed by Sasha Jovanovic
- Goldman Sachs has recently upgraded Sysmex Corporation from Neutral to Buy, citing improved medium to long-term growth prospects after the company confirmed an earnings bottom and reported better results from the previous quarter.
- This upgrade comes as concerns around earnings, especially in Sysmex’s China operations, are seen as already factored into the company’s current stock price, making its valuation more appealing relative to peers.
- We'll explore how the updated growth outlook, especially regarding Sysmex's China business, could influence its broader investment narrative.
The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
What Is Sysmex's Investment Narrative?
To be a Sysmex shareholder, you need to believe that the company can reinvigorate growth and restore earnings momentum despite setbacks in its key markets, especially China and Japan. The recent upgrade from Goldman Sachs is meaningful, suggesting that the worst of the earnings slide may be over and that the market has already priced in most of the foreseeable risks, particularly in China. This new vote of confidence could shift attention back to short-term catalysts like upcoming earnings releases and continued regulatory approvals for new products. However, lingering concerns remain, with revised earnings guidance and ongoing margin pressure, any further disappointment could amplify volatility. The attractiveness of Sysmex’s current share price, highlighted both by professional analysts and the recent upgrade, will likely sharpen focus on the company’s ability to deliver on its updated forecasts and regain lost ground after a rough year. But don’t overlook the uncertainty still clouding Sysmex’s China operations.
Sysmex's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other Perspectives
Explore 2 other fair value estimates on Sysmex - why the stock might be worth just ¥1899!
Build Your Own Sysmex Narrative
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Sysmex research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Sysmex research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sysmex's overall financial health at a glance.
Interested In Other Possibilities?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
- These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSE:6869
Sysmex
Engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software.
Excellent balance sheet established dividend payer.
Similar Companies
Market Insights
Community Narratives


